Business context and reporting period
This is Cerulean Pharma Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 31, 2017. Although the request metadata identifies Dare Bioscience, Dare was a proposed transaction counterparty; it is not the registrant in this filing. Cerulean was an oncology-focused, pre-revenue biotechnology company developing nanoparticle-drug conjugates (NDCs).
After year-end, Cerulean sold its two clinical-stage candidates, CRLX101 and CRLX301, to BlueLink Pharmaceuticals for $1.5 million, received March 21, 2017. It also agreed to sell its Dynamic Tumor Targeting platform to Novartis for $6.0 million, subject to closing conditions, and agreed to acquire Dare in a stock transaction, also subject to conditions and stockholder approval.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0.766 million | None |
| Research and development expense | $27.565 million | $25.948 million |
| General and administrative expense | $10.355 million | $11.224 million |
| Operating loss | $37.154 million | $37.172 million |
| Net loss | $39.305 million | $39.594 million |
| Net loss per share | $1.42 | $1.56 |
| Cash and cash equivalents at year-end | $34.950 million | $75.908 million |
| Working capital | $19.851 million | $60.965 million |
| Debt, including current portion | $12.821 million | $20.324 million |
2016 revenue came from the Novartis research collaboration: $0.507 million of the upfront fee was recognized and $0.259 million related to research activity. No product-sales revenue had been generated. At year-end, $4.493 million of collaboration consideration remained deferred. Operating cash outflow was $33.536 million, versus $31.915 million in 2015; cash declined by $40.958 million during 2016. The filing reports no meaningful positive operating margin: the company remained loss-making, with operating expenses far exceeding revenue.
Fourth-quarter 2016 revenue was $0.766 million; operating expenses were $5.274 million and net loss was $4.945 million. The company reported substantial doubt about its ability to continue as a going concern, stating that year-end cash was expected to fund operations only into the second half of 2017 under its operating plan. In March 2017, it paid Hercules $12.4 million and terminated the loan, including a $1.4 million final end-of-term charge.
Material changes versus the prior comparable period
- Annual revenue rose from zero to $0.766 million, entirely from collaboration activity; losses remained broadly stable, with net loss improving by $0.289 million.
- R&D expense increased 6%, mainly reflecting spending on CRLX101 and CRLX301; G&A expense declined 8% following cost controls and workforce reductions.
- Cash and working capital fell substantially as the company funded operations and repaid debt. Debt outstanding at year-end was $12.821 million, but was paid off in March 2017.
- In August 2016, the CRLX101-plus-Avastin Phase 2 renal-cell-carcinoma trial showed no statistically significant improvement in median progression-free survival or objective response rate versus standard of care. Cerulean discontinued development in that indication and reduced its workforce by approximately 48% during 2016.
- In March 2017, Cerulean sold CRLX101 and CRLX301, proposed the Novartis platform sale and Dare business combination, and announced a further workforce reduction of approximately 58%, to eight full-time-equivalent employees.
Outlook, risks and unusual items
Management expected 2017 expenses to decrease following restructuring and the sale of the clinical candidates. If the Novartis platform sale closed, Cerulean expected not to incur significant platform expenses. If it did not close, continuing platform operations would require additional funding and staffing. The Dare transaction could result in Dare’s selling stockholders owning approximately 51%–70% of Cerulean after closing; the exchange ratio depended on relative valuations and net cash positions.
Both the Dare transaction and Novartis asset sale required stockholder approval and other closing conditions; neither was assured. Failure to complete them could leave the company needing new capital, pursuing another transaction, or winding down and liquidating. The filing also notes potential termination fees, transaction-related litigation, dilution from future equity financing, clinical and regulatory uncertainty, dependence on third parties, and the possibility that liquidation reserves and obligations would reduce any distribution to stockholders. The auditor’s report highlights the going-concern uncertainty; the financial statements contain no adjustments for its possible outcome.
Most important facts for investors to verify
- Whether the Dare stock transaction and Novartis platform sale closed, and the final ownership split, consideration and transaction costs.
- Cash remaining after the $12.4 million Hercules payoff, the $1.5 million BlueLink proceeds, and any subsequent transaction proceeds or operating expenditures.
- Whether Cerulean obtained sufficient liquidity to continue operations, and the status of the going-concern uncertainty.
- The consequences of selling the clinical candidates and platform, including any remaining licenses, obligations, or potential milestone and royalty receipts.
- Whether the workforce reduction, lease amendment and other cost controls achieved the expected expense reductions.